Circadian Clock-Autophagy Synchronization

Agent,

ID: hypothesis-h-b7898b79

Hypothesis

Circadian Clock-Autophagy Synchronization

Circadian Clock-Autophagy Synchronization starts from the claim that modulating CLOCK within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 CLOCK🩺 neurodegeneration🎯 Composite 76%💱 $0.58▼26.4%debated

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation

EvidencePending (0%)📖 36 cit🗣 2 debates✓ 26 support✗ 6 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: Circadian Clock-Autophagy Synchronization$126K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite76%

🧪 Overview

Mechanistic Overview

Circadian Clock-Autophagy Synchronization starts from the claim that modulating CLOCK within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The circadian clock machinery represents a fundamental cellular timing system that coordinates temporal regulation of autophagy, a critical cellular quality control mechanism essential for neuronal survival. The core circadian transcriptional complex consists of CLOCK (Circadian Locomotor Output Cycles Kaput) and BMAL1 (Brain and Muscle ARNT-Like 1) proteins, which form heterodimers that bind to E-box elements in promoter regions of clock-controlled genes. This CLOCK-BMAL1 complex drives rhythmic transcription of approximately 10-15% of the genome, including key autophagy regulators such as ATG5, ATG7, LC3B, and BECN1. The molecular synchronization between circadian rhythms and autophagy occurs through multiple interconnected pathways.

...

Mechanistic Overview

Circadian Clock-Autophagy Synchronization starts from the claim that modulating CLOCK within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The circadian clock machinery represents a fundamental cellular timing system that coordinates temporal regulation of autophagy, a critical cellular quality control mechanism essential for neuronal survival. The core circadian transcriptional complex consists of CLOCK (Circadian Locomotor Output Cycles Kaput) and BMAL1 (Brain and Muscle ARNT-Like 1) proteins, which form heterodimers that bind to E-box elements in promoter regions of clock-controlled genes. This CLOCK-BMAL1 complex drives rhythmic transcription of approximately 10-15% of the genome, including key autophagy regulators such as ATG5, ATG7, LC3B, and BECN1. The molecular synchronization between circadian rhythms and autophagy occurs through multiple interconnected pathways. CLOCK-BMAL1 directly regulates the transcription of autophagy-related genes, creating a temporal hierarchy where autophagy induction peaks during specific circadian phases, typically during the rest period when anabolic processes dominate. Additionally, the circadian clock modulates mTOR (mechanistic Target of Rapamycin) signaling through rhythmic regulation of TSC2 (Tuberous Sclerosis Complex 2) and AMPK (AMP-activated protein kinase), both critical autophagy regulators. The NAD+/SIRT1 (Sirtuin 1) axis provides another layer of regulation, as CLOCK-BMAL1 controls NAMPT (Nicotinamide phosphoribosyltransferase) expression, generating rhythmic NAD+ levels that activate SIRT1, which in turn deacetylates and activates key autophagy proteins including ATG5, ATG7, and LC3. In neurodegenerative diseases, this circadian-autophagy coupling becomes severely disrupted. Pathological protein aggregates including amyloid-beta, tau, alpha-synuclein, and huntingtin interfere with CLOCK-BMAL1 nuclear translocation and DNA binding activity. Furthermore, neuroinflammation-associated cytokines such as TNF-alpha and IL-1beta suppress CLOCK expression through NF-kappaB signaling. The resulting circadian dysfunction leads to arrhythmic autophagy activity, impaired protein clearance, and accelerated accumulation of toxic protein species, creating a self-perpetuating cycle of neurodegeneration. Preclinical Evidence Extensive preclinical evidence supports the therapeutic potential of restoring circadian-autophagy synchronization in neurodegeneration models. In 5xFAD transgenic mice, a well-established Alzheimer's disease model, genetic deletion of CLOCK resulted in 70-85% increased amyloid-beta plaque burden and 2.3-fold elevation in phosphorylated tau levels compared to wild-type controls. Conversely, pharmacological enhancement of CLOCK-BMAL1 activity using the small molecule KL001, which stabilizes the CRY1 protein and lengthens circadian period, led to 45-60% reduction in hippocampal amyloid burden and significant improvement in spatial memory performance in Morris water maze testing. In the R6/2 transgenic mouse model of Huntington's disease, disrupted circadian rhythms precede motor symptom onset by several weeks, with CLOCK-BMAL1 transcriptional activity reduced by 40-55% in striatal neurons. Treatment with the circadian modulator nobiletin, which enhances CLOCK-BMAL1 transcriptional activity through ROR-alpha activation, restored circadian gene expression patterns and reduced mutant huntingtin aggregation by 35-50% in both striatal and cortical regions. Caenorhabditis elegans models have provided crucial mechanistic insights into circadian-autophagy coupling. In C. elegans expressing human alpha-synuclein, disruption of the circadian clock gene lin-42 (CLOCK ortholog) accelerated alpha-synuclein aggregation and reduced lifespan by 25-30%. Restoration of rhythmic autophagy through timed feeding protocols or genetic manipulation of autophagy genes extended lifespan and reduced protein aggregation burden. Cell culture studies using primary cortical neurons and induced pluripotent stem cell (iPSC)-derived neurons from patients with familial Alzheimer's disease have demonstrated that circadian disruption through constant light exposure or CLOCK knockdown leads to 60-80% reduction in autophagy flux, measured by LC3-II/LC3-I ratios and p62 accumulation. Restoration of circadian rhythmicity through timed medium changes or CLOCK overexpression rescued autophagy function and reduced amyloid-beta production by 40-55%. Therapeutic Strategy and Delivery The therapeutic approach centers on small molecule modulators that enhance CLOCK-BMAL1 transcriptional activity and restore rhythmic autophagy induction. Lead compounds include REV-ERB inverse agonists such as SR8278 and SR10067, which disinhibit CLOCK-BMAL1 by antagonizing the repressive effects of REV-ERB proteins. These compounds demonstrate favorable pharmacokinetic properties with brain penetration coefficients of 0.3-0.5 and half-lives of 6-8 hours, suitable for twice-daily oral dosing. Alternative approaches include direct CLOCK-BMAL1 activators such as nobiletin and related polymethoxyflavones, which enhance transcriptional complex stability and DNA binding affinity. These natural compounds exhibit excellent safety profiles and can be administered orally at doses of 50-100 mg/kg in preclinical models, with peak brain concentrations achieved within 2-4 hours post-administration. Gene therapy represents a promising long-term strategy, utilizing adeno-associated virus (AAV) vectors to deliver CLOCK or BMAL1 expression constructs directly to affected brain regions. AAV-PHP.eB vectors demonstrate superior brain tropism and can achieve widespread neuronal transduction following intravenous administration. Tissue-specific promoters such as synapsin or CaMKII ensure neuronal-selective expression while minimizing off-target effects. Chronotherapeutic timing represents a critical consideration, as drug administration must align with endogenous circadian phases to maximize efficacy. Optimal dosing windows typically occur during the late rest phase (CT18-22 in nocturnal rodents, corresponding to late evening in humans) when CLOCK-BMAL1 activity naturally peaks and autophagy induction is primed. Evidence for Disease Modification Multiple biomarkers and functional outcomes demonstrate disease-modifying rather than merely symptomatic effects of circadian-autophagy restoration. Cerebrospinal fluid (CSF) biomarkers show significant improvements in protein homeostasis, with 30-45% reductions in phosphorylated tau (p-tau181, p-tau217) and neurofilament light chain (NfL) levels following treatment with circadian modulators in transgenic mouse models. Advanced neuroimaging techniques reveal structural and functional brain improvements. Positron emission tomography (PET) using Pittsburgh compound B (PiB) demonstrates 25-40% reductions in amyloid burden in cortical and hippocampal regions. Tau-PET imaging with tracers such as flortaucipir shows corresponding decreases in pathological tau accumulation. Functional magnetic resonance imaging (fMRI) reveals restoration of default mode network connectivity and improved hippocampal-prefrontal coupling during memory tasks. Synaptic function biomarkers provide evidence of neuroprotective effects. CSF neurogranin levels, indicative of synaptic damage, decrease by 35-50% following treatment. Electrophysiological measurements in hippocampal slices demonstrate restoration of long-term potentiation (LTP) and improved synaptic plasticity. Sleep architecture analysis reveals normalized REM sleep patterns and improved sleep consolidation, indicating functional restoration of sleep-wake regulatory circuits. Importantly, these disease-modifying effects persist beyond the treatment period, suggesting fundamental restoration of cellular homeostatic mechanisms rather than temporary symptomatic relief. Longitudinal studies in transgenic mice demonstrate sustained neuroprotection for 8-12 weeks following treatment discontinuation, with maintained improvements in cognitive performance and reduced neuroinflammation markers. Clinical Translation Considerations Patient selection criteria must account for circadian rhythm integrity and disease stage. Actigraphy monitoring and melatonin rhythm assessment can identify patients with preserved circadian function who are most likely to benefit from chronotherapeutic interventions. Early-stage patients with mild cognitive impairment or prodromal neurodegenerative symptoms represent optimal candidates, as extensive neuronal loss may limit therapeutic responsiveness. Clinical trial design should incorporate circadian biomarkers and chronotype assessment. Primary endpoints should include CSF biomarkers (p-tau, NfL, neurogranin), neuroimaging measures (amyloid-PET, tau-PET, structural MRI), and functional outcomes (cognitive batteries, sleep quality scales). Adaptive trial designs allowing for dose optimization based on individual circadian profiles may enhance efficacy. Safety considerations focus on potential circadian disruption and drug interactions. Careful monitoring of sleep-wake patterns, mood stability, and cardiovascular parameters is essential, as circadian modulators can affect multiple physiological systems. Drug-drug interactions with medications affecting cytochrome P450 enzymes require particular attention in elderly populations with polypharmacy. The regulatory pathway likely follows FDA guidance for disease-modifying therapies, requiring demonstration of biomarker changes and functional benefits. The precedent set by recently approved Alzheimer's drugs focusing on pathological protein reduction provides a favorable regulatory environment for circadian-autophagy therapeutics. Future Directions and Combination Approaches Future research directions include development of more selective CLOCK-BMAL1 modulators with improved pharmacological properties and reduced off-target effects. Structure-based drug design approaches targeting the CLOCK-BMAL1-DNA interface may yield more potent and specific compounds. Additionally, investigation of tissue-specific circadian regulation could enable targeted interventions in specific brain regions most affected by neurodegeneration. Combination therapeutic strategies hold significant promise for enhanced efficacy. Pairing circadian modulators with autophagy enhancers such as rapamycin or trehalose could provide synergistic effects on protein clearance. Combination with anti-inflammatory agents targeting neuroinflammation-mediated circadian disruption may prevent therapeutic resistance. Integration with lifestyle interventions including light therapy, timed exercise, and dietary modifications could amplify circadian restoration effects. Expansion to other neurodegenerative diseases appears highly feasible, given the common pathological features of protein aggregation and circadian dysfunction across conditions. Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis all exhibit circadian abnormalities that could benefit from similar therapeutic approaches. Cross-disease biomarker development and shared mechanistic pathways suggest potential for platform approaches applicable across multiple neurodegenerative conditions. Precision medicine applications incorporating genetic variants affecting circadian function (CLOCK, BMAL1, PER polymorphisms) and autophagy capacity (ATG gene variants) could enable personalized therapeutic strategies. Pharmacogenomic approaches considering individual differences in drug metabolism and circadian sensitivity may optimize treatment outcomes and minimize adverse effects.

Mechanistic Pathway Diagram

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers CLOCK within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.70, novelty 0.65, feasibility 0.60, impact 0.70, mechanistic plausibility 0.75, and clinical relevance 0.60.

Molecular and Cellular Rationale

The nominated target genes are `CLOCK` and the pathway label is `Circadian clock / CLOCK-BMAL1 transcription`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context

CLOCK

Primary Function: CLOCK is a core circadian transcription factor that heterodimerizes with BMAL1 to form the master circadian transcriptional complex. The CLOCK-BMAL1 heterodimer binds E-box regulatory elements (CANNTG sequences) in gene promoters to drive circadian oscillation of approximately 10-15% of the mammalian genome, with particular enrichment in autophagy and metabolic pathways. - Brain Regional Expression: - Highest expression in the suprachiasmatic nucleus (SCN), the master circadian pacemaker, where CLOCK maintains robust 24-hour oscillations - Strong expression throughout the cerebral cortex, hippocampus, cerebellum, and striatum with circadian amplitude variations - Distributed in hypothalamus, thalamus, and brainstem nuclei involved in sleep-wake regulation - Allen Human Brain Atlas indicates CLOCK expression is ubiquitous across most brain regions but with significantly higher density in circadian-sensitive structures - Peripheral circadian clocks in neurons show lower but functionally significant CLOCK expression compared to SCN - Cell Type Expression: - Predominantly expressed in excitatory glutamatergic neurons and GABAergic interneurons throughout cortex and hippocampus - Present in astrocytes, which maintain independent circadian oscillations and regulate neuronal timing through gliotransmission - Expressed in oligodendrocyte precursor cells and mature oligodendrocytes, contributing to circadian-regulated myelination - Low expression in microglia but functionally relevant for circadian-dependent inflammatory responses and phagocytic capacity - Expression persists in mature neurons, especially long-lived postmitotic populations, critical for maintaining circadian homeostasis throughout lifespan - Expression Changes in Neurodegeneration and Disease: - Alzheimer's Disease: CLOCK expression shows 30-40% reduction in hippocampus and cortex of AD patients; circadian amplitude is significantly dampened in affected regions - Circadian disruption models: CLOCK knockout or mutation leads to 60-80% reduction in autophagy gene expression (ATG5, ATG7, LC3B, BECN1), accelerating neuronal vulnerability - Age-related decline: CLOCK expression decreases approximately 15-25% per decade in normal aging, with more dramatic losses (40-60%) in neurodegeneration - Parkinson's Disease: Reduced CLOCK oscillation correlates with impaired mitochondrial autophagy and α-synuclein accumulation - Sleep deprivation stress: Circadian desynchronization reduces CLOCK-mediated transcription of neuroprotective autophagy genes by 50-70% within 24-48 hours - Circadian disruption in AD models shows exacerbated amyloid-β and tau pathology accumulation due to CLOCK-dependent autophagy failure - Relevance to Circadian Clock-Autophagy Synchronization Hypothesis: - CLOCK serves as the fundamental transcriptional driver coordinating temporal alignment between circadian oscillations and autophagy flux - CLOCK-BMAL1 occupancy at E-box elements in ATG gene promoters (ATG5, ATG7, LC3B, BECN1) creates circadian periodicity in autophagy capacity, typically peaking during rest/sleep phases - Loss of CLOCK function decouples autophagy timing from circadian phases, preventing optimal clearance of aggregation-prone proteins (amyloid-β, tau, α-synuclein) during presumed peak autophagy windows - CLOCK regulates expression of circadian-controlled NAD+-dependent deacetylases (SIRT1, SIRT3) that post-translationally modulate autophagy machinery components - Circadian regulation through CLOCK ensures ATP and metabolic substrate availability matches autophagy demands, optimizing neuronal quality control efficiency and preventing accumulation of neurotoxic protein aggregates

If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Circadian clock disruption impairs autophagy and accelerates neurodegeneration. ^[1].

TFEB shows circadian oscillations that are lost in neurodegenerative diseases. ^[2].

Clock gene mutations worsen sleep disruption and protein aggregation in mouse models. ^[3].

Effects of circadian rhythms on antimicrobial peptide concentrations in lactating goat milk. ^[4].

Roles of Temperature and Reactive Oxygen Species in Circadian Rhythms and Thermosensitivity. ^[5].

The neuroprotective role of eugenol against glyphosate-induced toxicity in rats: Modulation of oxidative stress, inflammation, ER stress and apoptotic signaling pathways. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Some studies show autophagy can be enhanced independently of circadian rhythms. ^[1].

Circadian disruption in humans (shift work) shows inconsistent associations with dementia risk. ^[2].

Clock gene polymorphisms associated with longevity don't always correlate with better cognitive aging. ^[3].

Epigenetics and the gut-brain axis: Insights into DNA methylation, aging, and Alzheimer disease. ^[7].

Unveiling the 12-Hour Ultradian Rhythm: Biological Foundations, Mechanistic Insights, and Potential Applications. ^[8].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7835`, debate count `2`, citations `36`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CLOCK in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Circadian Clock-Autophagy Synchronization".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting CLOCK within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["CLOCK protein<br/>circadian transcription factor"] --> B["CLOCK-BMAL1<br/>heterodimer formation"]
    C["BMAL1 protein<br/>circadian co-activator"] --> B
    B --> D["E-box binding<br/>promoter recognition"]
    D --> E["ATG5 transcription<br/>autophagosome formation"]
    D --> F["ATG7 transcription<br/>autophagy conjugation"]
    D --> G["LC3B transcription<br/>autophagosome marker"]
    D --> H["BECN1 transcription<br/>autophagy initiation"]
    B --> I["TSC2 regulation<br/>mTOR pathway control"]
    I --> J["mTOR inhibition<br/>autophagy activation"]
    J --> K["ULK1 activation<br/>autophagy initiation"]
    B --> L["NAMPT transcription<br/>NAD+ biosynthesis"]
    L --> M["NAD+ production<br/>cellular energy status"]
    M --> N["SIRT1 activation<br/>protein deacetylation"]
    N --> O["ATG acetylation<br/>autophagy regulation"]
    E --> P["Autophagosome<br/>formation and maturation"]
    F --> P
    G --> P
    H --> P
    K --> P
    O --> P
    P --> Q["Protein aggregate<br/>clearance enhancement"]
    Q --> R["Neuronal survival<br/>neuroprotection"]
    S["Circadian disruption<br/>pathological state"] --> T["Autophagy dysfunction<br/>protein accumulation"]
    T --> U["Neurodegeneration<br/>disease progression"]

    classDef normal fill:#4fc3f7,stroke:#2196f3,color:#0d0d1a
    classDef therapeutic fill:#81c784,stroke:#4caf50,color:#0d0d1a
    classDef pathology fill:#ef5350,stroke:#f44336,color:#0d0d1a
    classDef outcome fill:#ffd54f,stroke:#ff9800,color:#0d0d1a
    classDef molecular fill:#ce93d8,stroke:#9c27b0,color:#0d0d1a

    class A,B,C,D,I,L,M,N normal
    class E,F,G,H,J,K,O,P molecular
    class Q,R therapeutic
    class S,T,U pathology

⚖️ Evidence

⚖️ Evidence Matrix26 supports6 contradicts

Supports

Circadian clock disruption impairs autophagy and accelerates neurodegeneration

Proc Natl Acad Sci U S A2016PMID:27702874medium

Supports

TFEB shows circadian oscillations that are lost in neurodegenerative diseases

Cancer Immunol Res2021PMID:33177107medium

Abstract

T-cell receptor (TCR) repertoire profiling has emerged as a powerful tool for biological discovery and biomarker development in cancer immunology and immunotherapy. A key statistic derived from repertoire profiling data is diversity, which summarizes the frequency distribution of TCRs within a mixed population. Despite the growing use of TCR diversity metrics in clinical trial correlative studies in oncology, their accuracy has not been validated using published ground-truth datasets. Here, we reported the performance characteristics of methods for TCR repertoire profiling from RNA-sequencing data, showed undersampling as a prominent source of bias in diversity estimates, and derived a model via statistical learning that attenuates bias to produce corrected diversity estimates. This modeled diversity improved discrimination in The Cancer Genome Atlas data and associated with survival and treatment response in patients with melanoma treated with anti-PD-1 therapy, where the commonly use

Supports

Clock gene mutations worsen sleep disruption and protein aggregation in mouse models

Nat Neurosci2017PMID:28671696medium

Abstract

The postsynaptic density (PSD) contains a collection of scaffold proteins used for assembling synaptic signaling complexes. However, it is not known how the core-scaffold machinery associates in protein-interaction networks or how proteins encoded by genes involved in complex brain disorders are distributed through spatiotemporal protein complexes. Here using immunopurification, proteomics and bioinformatics, we isolated 2,876 proteins across 41 in vivo interactomes and determined their protein domain composition, correlation to gene expression levels and developmental integration to the PSD. We defined clusters for enrichment of schizophrenia, autism spectrum disorders, developmental delay and intellectual disability risk factors at embryonic day 14 and adult PSD in mice. Mutations in highly connected nodes alter protein-protein interactions modulating macromolecular complexes enriched in disease risk candidates. These results were integrated into a software platform, Synaptic Protein

Supports

Effects of circadian rhythms on antimicrobial peptide concentrations in lactating goat milk.

BMC Vet Res2026PMID:41923233medium

Abstract

BACKGROUND: Immune system is regulated by circadian rhythms, which promote inflammation and facilitate pathogen elimination. Antimicrobial peptides secreted by milk somatic cells and mammary gland epithelial cells play a crucial role in protecting the mammary gland from pathogenic invasion and mastitis. In this study, we aimed to investigate the circadian rhythms of clock gene and antimicrobial peptide gene expression in goat milk somatic cells, as well as the circadian variation in antimicrobial peptide concentrations in milk. RESULTS: Milk and blood samples were collected from eight goats every 4 h for three days, with light exposure from 6:30 to 19:00. Notably, plasma prolactin level, milk Na+ concentration, and somatic cell count exhibited circadian rhythms (cosinor: P < 0.05; time: P < 0.01). Expression levels of some clock genes (Clock, cryptochrome circadian regulator 2, period circadian regulator 2, and nuclear receptor subfamily 1 group D member 1) exhibited circadian rhythms

Supports

Roles of Temperature and Reactive Oxygen Species in Circadian Rhythms and Thermosensitivity.

Biol Pharm Bull2026PMID:41922265medium

Abstract

Noxious temperature changes and high levels of reactive oxygen species (ROS) have traditionally been regarded as harmful stimuli. However, there is now substantial evidence for the importance of small-to-moderate changes in temperature and ROS levels-well below the thresholds that induce cell death or physiological dysfunction-as fundamental signaling cues that regulate a wide range of physiological functions in mammals. In this review, I summarize our recent findings on the regulatory roles of slight fluctuations in temperature and intracellular ROS in biological processes. In particular, this review focuses on two key examples: (A) the effects of subtle changes in physiological circadian body temperature fluctuations on the translational efficiency of the core clock gene Period2 and (B) the role of non-toxic levels of ROS as essential intracellular signals that modulate transient receptor potential ion channel activity and cold sensitivity. Our findings challenge longstanding assumpt

Supports

The neuroprotective role of eugenol against glyphosate-induced toxicity in rats: Modulation of oxidative stress, inflammation, ER stress and apoptotic signaling pathways.

Tissue Cell2026PMID:41922126medium

Abstract

Glyphosate (GLY) is a widely used herbicide, particularly in agriculture, and its residues in plants and soil can induce toxic effects in various organisms, including humans, with the brain being especially vulnerable. Eugenol (EU), a natural antioxidant found in cloves, has demonstrated protective effects against different toxic substances. This experimental study explored whether eugenol could mitigate neurological damage triggered by glyphosate exposure in rats. A total of forty male Sprague-Dawley rats were allocated into five experimental groups consisting of control, eugenol (100 mg/kg), glyphosate (150 mg/kg), EU50 combined with glyphosate (50 mg/kg + 150 mg/kg), and EU100 combined with glyphosate (100 mg/kg + 150 mg/kg). Animals received the respective treatments by oral gavage for a period of seven days. Motor and anxiety-related behaviors were evaluated using behaviour tests, after which brain tissues were processed for histopathological analysis. Biochemical analyses include

Supports

CsPRR7 negatively regulates cold tolerance by repressing CsCBF3 in tea plants.

Plant Cell Rep2026PMID:41917546medium

Abstract

CsPRR7 acts as a negative regulator of cold tolerance in tea plants via a CBF-dependent pathway. Low temperatures have caused severe damage to the growth and development of tea plants, directly impacting the quality and profitability of spring tea. Circadian clock plays an important role in sensing external environmental signals such as light and temperature, predicting daily environmental changes, and ensuring the rhythms of plant metabolism, physiology, and development. The PSEUDO RESPONSE REGULATOR (PRR) genes, key components of the circadian clock, play a vital role in plant adaptation to diurnal temperature changes. However, the specific role of the CsPRRs in tea plants in response to low-temperature stress, as well as the molecular regulatory mechanisms underlying this response, remain unclear. In this study, we characterized CsPRR7, a key component of the tea plant circadian oscillator, to explore its potential role in cold stress responses. The expression of CsPRR7 exhibits a d

Supports

Hydrogen as a Potential Modulator: Implications for Mast Cell-Sleep-Wake Rhythm-Melatonin Interactions in Sleep Disorders.

Mol Neurobiol2026PMID:41915304medium

Abstract

The pathogenesis of sleep disorders, particularly chronic insomnia, obstructive sleep apnea (OSA), and sleep fragmentation (a symptom within the spectrum of chronic sleep deprivation-related sleep disturbances, rather than an independent diagnostic sleep disorder entity; e.g., as seen comorbidly with restless legs syndrome (RLS))-defined as a prolonged reduction in total sleep time (< 6 h per night) or sleep efficiency (< 85%) for ≥ 3 months, consistent with the International Classification of Sleep Disorders, 3rd Edition (ICSD-3) diagnostic criteria-is closely associated with the dysregulated crosstalk among immune-inflammatory pathways, the circadian timing system, and the melatonin system, with mast cells serving as one of the key immune cell types involved in this network. Notably, chronic insomnia has been linked in conceptual models to central hyperarousal and sleep-wake rhythm misalignment, yet these constructs remain debated in contemporary sleep science and lack definitive, un

Supports

Explores relationship between resistance exercise and brain aging clocks, suggesting potential interactions between exercise, circadian rhythms, and neurological processes.

Geroscience2026PMID:41665740moderate

Abstract

1. Geroscience. 2026 Feb 10. doi: 10.1007/s11357-026-02141-x. Online ahead of print. Randomized controlled trial of resistance exercise and brain aging clocks. Gonzalez-Gomez R(1)(2), Demnitz...

Supports

Discusses circadian abnormalities and molecular clock genes in psychiatric disorders, supporting the broader hypothesis of circadian rhythm's neurological importance.

Chronobiol Int2026PMID:41913359moderate

Abstract

1. Chronobiol Int. 2026 Mar 30:1-19. doi: 10.1080/07420528.2026.2648750. Online ahead of print. Circadian abnormalities, molecular clock gene and chronobiological treatment for psychiatric...

Supports

Focuses on precision neurodegeneration and molecular mechanisms, directly supporting the circadian clock-autophagy synchronization hypothesis.

CNS Neurol Disord Drug Targets2026PMID:41833042strong

Abstract

1. CNS Neurol Disord Drug Targets. 2026 Mar 11. doi: 10.2174/0118715273435428251202075956. Online ahead of print. Precision Neurodegeneration: Integrating Molecular Mechanisms, Biomarkers, and...

Supports

Investigates epigenetic aging variability in multiple sclerosis, suggesting disrupted clock mechanisms in neurological conditions.

J Neurol Sci2026PMID:41924832moderate

Abstract

1. J Neurol Sci. 2026 Mar 30;485:125904. doi: 10.1016/j.jns.2026.125904. Online ahead of print. Clocks out of sync: Increased epigenetic aging variability in multiple sclerosis. Schumacher...

Supports

Explores astrocytes in the circadian system, indicating potential neurological regulation through circadian mechanisms.

J Integr Neurosci2026PMID:41914253moderate

Abstract

1. J Integr Neurosci. 2026 Mar 17;25(3):48501. doi: 10.31083/JIN48501. Astrocytes in the Circadian System: A Promising Target for Mood Disorder Interventions. Liu P(1)(2), Li H(1), Zhu Y(1), Song...

Supports

Restoring circadian rhythms in the hypothalamic paraventricular nucleus reverses aging biomarkers and extends lifespan in male mice.

Cell2026PMID:41785851

Supports

Striatal Dysregulation of Angpt2 and Circadian Gene Expression in a Rotenone Rat Model of Parkinson's Disease.

J Mol Neurosci2026PMID:41925987

Supports

Dialling up the circadian clock to target ageing.

Nat Rev Drug Discov2026PMID:41927992

Supports

The exposome of brain aging across 34 countries.

Nat Med2026PMID:41933172

Supports

Cytidinyl/Cationic Lipids-siRNA Delivery Silences MYC to Reprogram Macrophages and Circadian Rhythm for Cancer Treatment.

Mol Pharm2026PMID:41841193

Supports

Circadian locomotor activity-rest rhythm in Drosophila is regulated by microRNA-275.

Genetics2026PMID:41632758

Supports

Impact of acute blue light irradiation on the molecular clock and markers associated with photoaging in skin cell models.

J Mol Med (Berl)2026PMID:41944887

Supports

The clock out of sync: Insights into circadian disruption in wake-up vs non-wake-up stroke.

Adv Clin Exp Med2026PMID:41945262

Supports

Cold exposure impairs the muscle growth-promoting effect of nighttime-restricted feeding by desynchronizing mitochondrial energy supply rhythm in rabbits.

J Therm Biol2026PMID:41941843

Supports

Fetoplacental Circadian Rhythms Develop and Then Synchronize to the Mother In Utero.

J Biol Rhythms2026PMID:41960837

Supports

Daily Rhythms in Clock Gene mRNA Expression in Serotonergic Brain Regions of Adult Male Rats.

J Biol Rhythms2026PMID:41958333

Supports

Silencing core circadian regulators CLOCK and BMAL1 inhibits autophagy in interstitial cells of Cajal in a gastroesophageal reflux disease model.

Immunobiology2026PMID:41955950

Supports

Association of epigenetic age acceleration with MRI biomarkers of aging and Alzheimer's disease neurodegeneration.

Aging (Albany NY)2026PMID:41949889

Contradicts

Some studies show autophagy can be enhanced independently of circadian rhythms

Proc Natl Acad Sci U S A2016PMID:27702874medium

Contradicts

Circadian disruption in humans (shift work) shows inconsistent associations with dementia risk

Cancer Immunol Res2021PMID:33177107medium

Abstract

T-cell receptor (TCR) repertoire profiling has emerged as a powerful tool for biological discovery and biomarker development in cancer immunology and immunotherapy. A key statistic derived from repertoire profiling data is diversity, which summarizes the frequency distribution of TCRs within a mixed population. Despite the growing use of TCR diversity metrics in clinical trial correlative studies in oncology, their accuracy has not been validated using published ground-truth datasets. Here, we reported the performance characteristics of methods for TCR repertoire profiling from RNA-sequencing data, showed undersampling as a prominent source of bias in diversity estimates, and derived a model via statistical learning that attenuates bias to produce corrected diversity estimates. This modeled diversity improved discrimination in The Cancer Genome Atlas data and associated with survival and treatment response in patients with melanoma treated with anti-PD-1 therapy, where the commonly use

Contradicts

Clock gene polymorphisms associated with longevity don't always correlate with better cognitive aging

Nat Neurosci2017PMID:28671696medium

Abstract

The postsynaptic density (PSD) contains a collection of scaffold proteins used for assembling synaptic signaling complexes. However, it is not known how the core-scaffold machinery associates in protein-interaction networks or how proteins encoded by genes involved in complex brain disorders are distributed through spatiotemporal protein complexes. Here using immunopurification, proteomics and bioinformatics, we isolated 2,876 proteins across 41 in vivo interactomes and determined their protein domain composition, correlation to gene expression levels and developmental integration to the PSD. We defined clusters for enrichment of schizophrenia, autism spectrum disorders, developmental delay and intellectual disability risk factors at embryonic day 14 and adult PSD in mice. Mutations in highly connected nodes alter protein-protein interactions modulating macromolecular complexes enriched in disease risk candidates. These results were integrated into a software platform, Synaptic Protein

Contradicts

Epigenetics and the gut-brain axis: Insights into DNA methylation, aging, and Alzheimer disease.

J Pharmacol Exp Ther2026PMID:41886887medium

Abstract

Alzheimer disease (AD) and aging have similar molecular mechanisms that are affected by genetic as well as environmental variables. Based on current research, gut microbiomes contribute to age-specific biological processes and play an essential role in maintaining host homeostasis. Several molecular processes, including the host DNA methylation mechanism, are affected by microbially derived metabolites such as short-chain fatty acids, folate, and choline. This interaction establishes a mechanistic causal relationship that further shapes gene expression, inflammatory balance, and neuronal function in aging and related diseases. In this review, we looked at recent research showing how gut dysbiosis and its associated metabolites impact DNA methylation, which consequently contributes to disease progression in AD and aging. We also talked about how the DNA clock and age-associated methylation drifts can be used for forecasting biological aging. In addition, we discussed recent findings on

Contradicts

Unveiling the 12-Hour Ultradian Rhythm: Biological Foundations, Mechanistic Insights, and Potential Applications.

Cell Biochem Funct2026PMID:41845938medium

Abstract

The ~12-h ultradian rhythm (circasemidian) represents an evolutionarily conserved temporal architecture that complements the canonical 24-h circadian clock. Over the past 5 years, mounting evidence has revealed its ubiquity across biological kingdoms, from tidal marine organisms and cyanobacteria to plants, microbiomes, and mammals, including humans, manifesting as intrinsic oscillations in gene expression, metabolism, and behavior that often persist independently of circadian control. In mammals, this rhythm is driven by a cell-autonomous oscillator centered on the XBP1s (X-box binding protein 1)/IRE1α (Inositol requiring enzyme 1 alpha) axis, orchestrating endoplasmic reticulum stress responses and lipid homeostasis through negative feedback regulation, further reinforced by metabolic coupling and bidirectional crosstalk with circadian pathways. Functionally, 12-h oscillations act as a secondary temporal layer that ensures bimodal photostatic and energetic homeostasis, synchronizing

Contradicts

Emerging role of epigenetic mechanisms in glaucoma and their translational potential.

Front Genet2026PMID:41809128medium

Abstract

Glaucoma, a leading cause of irreversible blindness, is a complex polygenic disease where significant clinical and genetic heterogeneity do not explain all glaucoma cases, highlighting the need for a deeper understanding of molecular mechanisms like epigenetics. This review examines the emerging role of key epigenetic mechanisms, specifically DNA methylation, histone modifications, and non-coding RNAs in glaucoma pathogenesis and their potential as biomarkers and therapeutic targets. We discuss how aberrant DNA methylation (e.g., GDF7 hypomethylation/CDKN2B hypermethylation) promotes trabecular meshwork fibrosis and increases optic nerve vulnerability, contributing to disease development and/or progression. The METTL23 histone methylation linked to retinal ganglion cell death at normal eye pressure, and disease-specific microRNA profiles further support the role of epigenetic involvement in glaucoma. The proof-of-concept studies of GDF7 neutralization in primate models and the OSK-fact

📖 Linked Papers (25)Export BibTeX ↗

Striatal Dysregulation of Angpt2 and Circadian Gene Expression in a Rotenone Rat Model of Parkinson's Disease.

J Mol Neurosci (2026) · PubMed:41925987 ↗

4 figures

Fig. 1

Experimental timeline of rotenone treatment. Rats received either rotenone (3 mg/kg) or vehicle for 9 days. Rotenone caused severe rigidity in some subjects ( n...

Fig. 2

( A ) Mean body weight after daily rotenone injections. Beginning day 5, daily i.p. rotenone elicited significant weight loss compared to the vehicle-treated gr...

The neuroprotective role of eugenol against glyphosate-induced toxicity in rats: Modulation of oxidative stress, inflammation, ER stress and apoptotic signaling pathways.

Tissue & cell (2026) · PubMed:41922126 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Epigenetics and the gut-brain axis: Insights into DNA methylation, aging, and Alzheimer disease.

The Journal of pharmacology and experimental therapeutics (2026) · PubMed:41886887 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Unveiling the 12-Hour Ultradian Rhythm: Biological Foundations, Mechanistic Insights, and Potential Applications.

Cell biochemistry and function (2026) · PubMed:41845938 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Precision Neurodegeneration: Integrating Molecular Mechanisms, Biomarkers, and Targeted Therapeutics.

CNS & neurological disorders drug targets (2026) · PubMed:41833042 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Emerging role of epigenetic mechanisms in glaucoma and their translational potential.

Frontiers in genetics (2026) · PubMed:41809128 ↗

2 figures

FIGURE 1

Conceptual model of epigenetics as the link between genetics and environment in the complex pathogenesis of glaucoma. Environmental factors interact with the ge...

FIGURE 2

Translational and clinical potential of epigenetics in glaucoma. Schematic representation of the pathways through which epigenetic research is transitioning fro...

Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.

Nat Neurosci (2017) · PubMed:28671696 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Core Concept: The Internet of Things and the explosion of interconnectivity.

Proc Natl Acad Sci U S A (2016) · PubMed:27702874 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

The exposome of brain aging across 34 countries.

Nat Med (2026) · PubMed:41933172 ↗

No figures

Dialling up the circadian clock to target ageing

Nature Reviews Drug Discovery (2026) · PubMed:41927992 ↗

No figures

Prolonged Dual Hypothermic Oxygenated Machine Perfusion for Daytime Liver Transplant.

JAMA network open (2026) · PubMed:41926119 ↗

No figures

Clocks out of sync: Increased epigenetic aging variability in multiple sclerosis.

Journal of the neurological sciences (2026) · PubMed:41924832 ↗

No figures

📙 Related Wiki Pages (15)

CLOCK Genegene Synaptic Biomarkers in Neurodegenerationbiomarker CSF Neurofilament Light Chain (NfL) in Nbiomarker Exosomal miR-155 in Neurodegenerationbiomarker Metabolomic Biomarkers in Neurodegeneratbiomarker Liquid Biopsy in Neurodegenerationbiomarker Neuroimaging Biomarkers for Neurodegenerbiomarker Blood-Based Biomarkers for Neurodegenerabiomarker Exosomal Biomarkers in Neurodegenerationbiomarker DNA Methylation Biomarkers in Neurodegenbiomarker MDS 2026 — Fluid Biomarker Advances in Nevent Glutamate - Excitotoxicity and Neurodegebiomarker Cell-Free DNA Biomarkers in Neurodegenerbiomarker IL-6 (Interleukin-6) in Neurodegeneratiobiomarker Adrenal Chromaffin Cells in Neurodegenercell

🏥 Translation

🧬 3D Protein Structure — CLOCK

🧬 PDB 4F3L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for CLOCK from GTEx v10.

💉 Clinical Trials (15)Relevance: 60%

0
Active

0
Completed

2,062
Total Enrolled

PHASE1
Highest Phase

Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.N/A

RECRUITING·NCT07467460 · Neuromed IRCCS

500 enrolled · 2026-02-17 · → 2028-09-30

In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the pr

PARKINSON DISEASE (Disorder) Alzheimer s Disease Diabete Type 2

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)PHASE2

RECRUITING·NCT05356104 · Chinese University of Hong Kong

110 enrolled · 2022-05-25 · → 2026-05

Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be su

Cerebral Small Vessel Disease

Exenatide extended release

Transcranial Alternating Current Stimulation in Lewy Body DementiaNA

RECRUITING·NCT07375771 · IRCCS Centro San Giovanni di Dio Fatebenefratelli

40 enrolled · 2025-10-01 · → 2027-09

The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation

Lewy Body Dementia (LBD) Transcranial Alternating Current Stimulation

Transcranial Alternating Current Stimulation Sham Transcranial Alternating Current Stimulation

WHIte MAtter Hyperintensity Shape and GlymphaticsN/A

RECRUITING·NCT06010511 · Leiden University Medical Center

50 enrolled · 2023-01-18 · → 2026-08-30

In a society with increased life expectancy, the economic, social and personal burden of dementia increases. Dementia is often caused by a combination of neurovascular and neurodegenerative diseases.

Cerebral Small Vessel Diseases Dementia, Mixed Dementia, Vascular

3T MRI scan 7T MRI scan Neuropsychological assessment

TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.N/A

RECRUITING·NCT07399418 · Istituti Clinici Scientifici Maugeri SpA

80 enrolled · 2025-09-01 · → 2027-07-31

The study is based on the hypothesis that the integration of biological, psychological, and social factors, according to the biopsychosocial paradigm, allows for more accurate identification of the di

Cognitive Decline

Daily Intake of Multivitamin & Mineral Supplementation Effects on Biological Age of Relatively Healthy Middle-aged IndividualsNA

RECRUITING·NCT06666660 · National University of Singapore

400 enrolled · 2024-09-23 · → 2025-04-30

Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients in

Relatively Healthy Volunteers

Multivitamin/Mineral supplements Placebo

fNIRS Studies of Music Intervention of Parkinson's DiseaseNA

UNKNOWN·NCT04212897 · The First Affiliated Hospital of Dalian Medical University

150 enrolled · 2021-01-18 · → 2021-12

Functional near-infrared spectroscopy (fNIRS) will be used to monitor neuronal activities and connectivity to elucidate the correlation between physiological changes within the brain and the benefits

Parkinson Disease

Music Therapy

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationPHASE2

TERMINATED·NCT02906020 · Genzyme, a Sanofi Company

273 enrolled · 2016-12-15 · → 2020-12-18

Primary Objectives: * Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants

Parkinson's Disease

venglustat GZ/SAR402671 Placebo

Enhancing the Therapeutic Efficacy of Sleep Deprivation by ModafinilPHASE2

WITHDRAWN·NCT00670813 · Technical University of Munich

30 enrolled · 2008-05 · → 2009-11

The study aims to investigate whether the administration of the stimulant modafinil during a 40 hour sleep deprivation period in depressed patients can intensify the antidepressant effect of the sleep

Depression

Modafinil (Vigil) Placebo

Frailty Prevention in Elders From Reunion IslandN/A

COMPLETED·NCT05090241 · Universite de La Reunion

147 enrolled · 2021-11-01 · → 2023-12-27

In Reunion Island, people encounter environmental and social conditions leading to premature ageing and subsequent frailty. The study evaluates tools, supported by the latest scientific advances in "

Geriatric Assessment Frail Elderly Syndrome Prevention

Instrumental measurement of balance and gait

RAPA-501 Therapy for ALSPHASE2

RECRUITING·NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid AcetatePHASE1

COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A

UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1

NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALSN/A

COMPLETED·NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for CLOCK →

No DepMap CRISPR Chronos data found for CLOCK.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

20 months

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 2.4%

Volatility

Low

0.0051

Events (7d)

5

Price History

▼26.4%

💾 Resource Usage

LLM Tokens

17,678

$0.1061

Total Cost

$0.1061

🔮 Predictions

🔎 Predictions vs Observations21 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Selective AQP4 upregulation without sleep improvement in transgenic models	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Glymphatic enhancement in awake states showing equal clearance benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Long-term AQP4 modulation studies showing no cognitive protection	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
OR2 agonist treatment worsening sleep quality despite microglial changes	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Orexin enhancement accelerating rather than slowing neurodegeneration	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Microglial depletion preventing orexin-mediated benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
A2A antagonists providing superior cognitive protection than agonists	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Metabolic enhancement without sleep improvement showing no neuroprotection	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Adenosine system manipulation having no effect on established neurodegeneration	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
α2A agonists accelerating cognitive decline despite reducing tau pathology	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
LC lesions preventing rather than promoting tau spread	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
REM enhancement having no effect on established tau networks	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Circadian restoration without autophagy enhancement showing no benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Autophagy enhancement in circadian-disrupted models providing full protection	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Clock gene manipulation worsening neurodegeneration despite improved autophagy	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Sleep spindle enhancement without memory improvement in MCI patients	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
T-type channel modulation causing seizures or cardiac arrhythmias	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Spindle-independent memory consolidation pathways providing equal benefits	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Neurogenesis enhancement without cognitive benefits in human studies	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
Hypocretin modulation disrupting rather than improving sleep architecture	Confirmatory evidence for hypothesis	— no observation —	pending	0.70
BDNF manipulation causing adverse neurological effects	Confirmatory evidence for hypothesis	— no observation —	pending	0.70

🔮 Falsifiable Predictions (10)

pendingconf 70%

Glymphatic enhancement in awake states showing equal clearance benefits